Latest From Biotech Now

Gates to contribute $50M for Ebola response


Bill Gates was on MSNBC’s Morning Joe to discuss the Gates Foundation’s contribution of $50 million to support emergency response to Ebola. Mr. Gates responded to criticism that the U.S. was initially slow to properly address the African crisis. He noted that it would be virtually impossible to respond much quicker to the unprecedented scale of the outbreak. He did call upon other countries to step up and dedicate resources as well. The most recent Read More >

Corporate, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Is the Next “Green Revolution” Right Around the Corner?

golden rice

“Modern supercrops will be a big help. But agriculture can’t be fixed by biotech alone.” National Geographic’s October issue contains an in-depth article, “The Next Green Revolution” on how plant biotechnology will be one part of a multifaceted solution to feeding a rapidly growing population in the face of climate change. Climate change and population growth will make life increasingly precarious for small farmers in the developing world – and for the people they feed. For most of Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Investor Forum Company Snapshot: Syntrix Biosystems


1.     What is your company’s lead product or technology? Omnitram (O-desmethyltramadol) is a novel  oral analgesic developed by Syntrix that alleviates pain via a dual mechanism involving mu-opioid receptor activation and inhibition of the reuptake of norepinephrine.  Omnitram is in clinical development and has just completed a Phase 1b double-blind, placebo-controlled clinical trial (N=40) in experimental pain. 2.     What sets your company apart from competitors? Omnitram is a proprietary solution for pain relief that is Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO’s 2014 Pacific Rim Summit Programming Will Put India in the Spotlight


In a recent article, The Hindu argues why India needs to start expanding its foot print in the rapidly advancing field of Synthetic Biology. G. Padmanaban explains that Synthetic Biology has garnered so much “hype” because scientists are looking for better ways to construct new organisms performing unique functions such as processing signals, storing information and carrying out analogue functions. That being said, the growth of Synthetic Biology is still being met with some roadblocks in India: “MNCs Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Patient and Venture Philanthropy Groups Presenting at 2014 BIO Investor Forum

BIO Investor Forum

BIO’s alliance development team works to foster collaboration between the biotech industry and nonprofit disease foundations. In recent years, many nonprofit foundations have become more engaged in the drug development process – whether they have created clinical trial recruitment tools, established a disease registry, or funded emerging biotech companies. Recognizing the value of these initiatives to expedite research and drug development, BIO provides opportunities for venture philanthropies and patient organizations to connect with BIO members Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,